Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: Possible regulation of pro-MMP-2 activation by TIMP-2

Journal of Pathology

Volumn 202, Issue 4, 2004, Pages 403-411

  Kayano, Kaori ^a   Shimada, Taketoshi ^a   Shinomiya, Takashi ^a   Nakai, Shigeru ^a   Hisa, Yasuo ^a   Aoki, Takanori ^b   Seiki, Motoharu ^c   Okada, Yasunori ^d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Daiichi Fine Chemical Co Ltd   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Activation of pro MMP 2; Adenocarcinoma; Adenoid cystic carcinoma; MMP; MT1 MMP; Mucoepidermoid carcinoma; Salivary gland; TIMP 2

Indexed keywords

1,10 PHENANTHROLINE; ANTINEOPLASTIC AGENT; COLLAGENASE 3; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; ORAL SURGERY; PRIORITY JOURNAL; PROTEIN FAMILY; SALIVARY GLAND CARCINOMA; TISSUE HOMOGENATE; ZYMOGRAPHY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENZYME ACTIVATION; ENZYME PRECURSORS; FEMALE; GELATIN; GELATINASES; HUMANS; MALE; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; SALIVARY GLAND NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 1842479296     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1541     Document Type: Article

References (31)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
2. Okada Y. Proteinases and matrix degradation. In Kelley's Textbook of Rheumatology (6th edn), Ruddy S, Harris ED Jr, Sledge CB (eds). WB Saunders: Philadelphia, 2001; 55-72.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-174.
4. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003; 22: 145-152.
5. Seiki M, Yana I. Role of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003; 94: 569-574.
6. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996; 69: 9-16.
7. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055-2060.
8. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999; 59: 467-473.
9. Shimada T, Nakamura H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis 2000; 18: 179-188.
10. Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998; 273: 16 098-16 103.
11. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871-880.
12. Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 1985; 146: 51-58.
13. Seifert G. Histological Typing of Salivary Gland Tumours. World Health Organization International Histological Classification of Tumours (2nd edn). Springer-Verlag: Berlin, 1991; 1-113.
14. Ward MJ, Levine PA. Salivary gland tumors. In Essentials of Head and Neck Oncology, Close LG, Larson DL, Shah JP (eds). Thime Medical Publishers: New York, 1998; 146-157.
15. LiVolsi VA, Merino MJ. Salivary gland tumors: Histopathology of salivary gland tumors. In Cancer of the Head and Neck, Ariyan S (ed). CV Mosby: St Louis, MO, 1987; 603-665.
16. Wenig BM. General principles of head and neck pathology: salivary gland malignant neoplasms. In Head and Neck Cancer: A Multidisciplinary Approach, Harrison LB, Session RB, Hong WK (eds). Lippincott-Raven: Philadelphia, 1999; 307-312.
17. Eisele DW, Johns ME. Salivary gland neoplasms. In Head and Neck Surgery - Otolaryngology (2nd edn), Bailey BJ, Calhoun KH (eds). Lippincott-Raven: Philadelphia, 1998; 1485-1508.
18. Azuma M, Tamatani T, Fukui K, et al. Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. Int J Cancer 1993; 54: 669-676.
19. Soini Y, Autio-Harmainen H. Synthesis and degradation of basement membranes in benign and malignant salivary gland tumours. A study by in situ hybridization. J Pathol 1993; 170: 291-296.
20. Aoki T, Yonezawa K, Ohuchi E, et al. Two-step sandwich enzyme immunoassay using monoclonal antibodies for detection of soluble and membrane-associated human membrane type 1-matrix metalloproteinase. J Immunoassay Immunochem 2002; 23: 49-68.
21. Fujimoto N, Iwata K. Use of EIA to measure MMPs and TIMPs. In Methods in Molecular Biology, Clark IM (ed), vol 151. Humana Press: Totowa, 2001; 347-358.
22. Fujimoto N, Zhang J, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 1993; 220: 31-45.
23. Johansson N, Ala-aho R, Uitto VJ, et al. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 2000; 113: 227-235.
24. Johansson N, Airola K, Grenman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499-508.
25. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-428.
26. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999; 84: 470-477.
27. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995; 64: 355-359.
28. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-3266.
29. Hotary KB, Allen ED, Brooks PC, et al. Membrane type 1 matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114: 33-45.
30. Eversole LR. Histogenic classification of salivary tumors. Arch Pathol 1971; 92: 433-443.
31. Regezi JA, Batsakis JG. Histogenesis of salivary gland neoplasms. Otolaryngol Clin North Am 1977; 10: 297-307.